Feb. 13 at 8:35 PM
$AUTL Key Points of this Agreement:
Strategic alliance leverages manufacturing/commercial infrastructure as well as technology w/ aim to advance both companies’ auto CAR-T programs to market
*
$BNTX secures right to use AUTL’s manufacturing capacity in a cost-efficient set-up to accelerate development of BNT211 into pivotal trials in CLDN6+ tumors
* BNTX to support launch & expansion of development program of AUTL’s lead cell therapy candidate obe-cel & will receive a royalty on net sales
* BNTX has co-commercialization options for AUTO1/22 & AUTO6NG programs
* BNTX has option to access suite of AUTL target binders & cell programming technologies to support BNTX’s development of in vivo cell therapy & antibody-drug conjugate candidates
* BNTX has agreed to purchase
$200 million of Autolus’ ADS in a private placement. BNTX will have a right to appoint director to AUTL Board.
* BNTX to make a cash payment of
$50 mil for
BNTX to receive an up to mid-single digit royalty on obe-cel net sales.
